[{"address1": "11711 N. Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "(317) 659-0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 38, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 55, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 571200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard B. Bartram CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 578000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven J. Prestrelski M.B.A., MBA, Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 57, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Dorato DABT, Ph.D.", "title": "Sr. Vice President of Discovery & Non-Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.54, "open": 10.56, "dayLow": 9.821, "dayHigh": 10.96, "regularMarketPreviousClose": 10.54, "regularMarketOpen": 10.56, "regularMarketDayLow": 9.821, "regularMarketDayHigh": 10.96, "forwardPE": -4.3357987, "volume": 224922, "regularMarketVolume": 224922, "averageVolume": 212772, "averageVolume10days": 292950, "averageDailyVolume10Day": 292950, "bid": 9.91, "ask": 10.03, "bidSize": 100, "askSize": 100, "marketCap": 330498112, "fiftyTwoWeekLow": 9.65, "fiftyTwoWeekHigh": 27.5, "fiftyDayAverage": 18.7744, "twoHundredDayAverage": 20.589195, "currency": "USD", "enterpriseValue": 53645264, "floatShares": 13851854, "sharesOutstanding": 33417400, "sharesShort": 1674966, "sharesShortPriorMonth": 485164, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.050100002, "heldPercentInsiders": 0.03243, "heldPercentInstitutions": 0.91968, "shortRatio": 5.2, "impliedSharesOutstanding": 35613700, "bookValue": 8.131, "priceToBook": 1.2163327, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -55179000, "trailingEps": -1.65, "forwardEps": -2.33, "enterpriseToEbitda": -0.904, "52WeekChange": -0.5818182, "SandP52WeekChange": 0.23631513, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MBX", "underlyingSymbol": "MBX", "shortName": "MBX Biosciences, Inc.", "longName": "MBX Biosciences, Inc.", "firstTradeDateEpochUtc": 1726234200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a066c197-b79d-33dd-be3a-0bcc20467a16", "messageBoardId": "finmb_613097171", "gmtOffSetMilliseconds": -18000000, "currentPrice": 9.89, "targetHighPrice": 44.0, "targetLowPrice": 30.0, "targetMeanPrice": 37.25, "targetMedianPrice": 37.5, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 277063008, "totalCashPerShare": 8.291, "ebitda": -59348000, "totalDebt": 210000, "quickRatio": 25.451, "currentRatio": 25.748, "debtToEquity": 0.077, "operatingCashflow": -49790000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]